29 April 2008
The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipientsSilvia TirelliA, Mariano FerraressoACDE, Luciana GhioBD, Elisa MeregalliF, Valentina MartinaB, Mirco BelingheriF, Camilla MattielloF, Emilio TorresaniG, Alberto EdefontiG
Med Sci Monit 2008; 14(5): CR251-254 :: ID: 855750
CYP3A5 gene polymorphism has been shown to influence tacrolimus (TAC) blood concentration and dose requirement in adult kidney transplant patients. The aim was to analyze retrospectively the modification induced by CYP3A5 gene polymorphism on TAC's pharmacokinetic parameters obtained from 26 adolescents receiving TAC as their main immunosuppressive drug.
Material and Method
The adolescent kidney transplant patients were genotyped for CYP3A5*3 and grouped accordingly. TAC dose, blood levels, and dose-normalized TAC blood concentration and volume of distribution obtained at different post-transplant periods during the first post-transplant year were correlated with the corresponding genotype.
During the first three months post-transplant, heterozygotes (CYP3A5*1/*3) displayed a lower TAC blood concentration than homozygotes (CYP3A5*3/*3) (at 1 month: 7.8+/-2.1 vs. 13.4+/-6 ng/ml, p=0.007) despite a therapeutic monitoring strategy. Between 3-12 months post-transplant, TAC blood concentration was comparable between the two groups, but a two-fold increase in the daily drug dose was necessary for the heterozygotes (at 6 months: 0.23+/-0.1 vs. 0.13+/-0.06 mg/kg, p=0.04). The dose-normalized TAC concentration [(ng/ml)/(mg/kg)] was significantly lower in patients displaying the CYP3A5*1/*3 polymorphism (at 2 weeks: 33+/-2.16 vs. 71.1+/-37.8, p=0.01; 6 months: 35.4+/-12.9 vs. 85.2+/-58.9, p=0.01). At the same time, the volume of distribution of the drug in the latter group was distinctly increased for the entire post-transplant year (at 6 months: 1.79+/-0.42 vs. 0.73+/-0.5 l/kg, p=0.001).
The great influence of CYP3A5 on the pharmacokinetics and pharmacodynamics of TAC in young transplant recipients suggests the need for pre-transplant screening of this polymorphism to improve TAC therapy.
Keywords: Tacrolimus - pharmacokinetics, Polymorphism, Genetic, Kidney Transplantation - methods, Kidney - drug effects, Immunosuppressive Agents - pharmacokinetics, Homozygote, Heterozygote, Genotype, Cytochrome P-450 CYP3A - genetics, Polymorphism, Single Nucleotide, Child, Alleles, Adolescent
01 December 2021 : EditorialEditorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
Med Sci Monit 2021; 27:e935624
03 December 2021 : Laboratory ResearchInfluenza and Influenza-Like Respiratory Virus Infections in Children During the 2019/20 Influenza Season a...
Med Sci Monit In Press; DOI: 10.12659/MSM.934862
08 November 2021 : Database AnalysisVirtual Screening and Molecular Docking to Study the Mechanism of Chinese Medicines in the Treatment of Cor...
Med Sci Monit In Press; DOI: 10.12659/MSM.934102
01 November 2021 : EditorialEditorial: What Can be Learned from National and International Vaccine Adverse Event Reporting Systems Duri...
Med Sci Monit 2022; 28:e935299
07 Dec 2021 : Review articleA Review of the Impact of Neutrophils and Neutrophil Extracellular Traps (NETs) on the Development of Aorti...
Med Sci Monit In Press; DOI: 10.12659/MSM.935134
07 Dec 2021 : Review articleAdie’s Pupil: A Diagnostic Challenge for the Physician
Med Sci Monit In Press; DOI: 10.12659/MSM.934657
06 Dec 2021 : Animal ResearchAstragalus Flavone Induces Proliferation and Differentiation of Neural Stem Cells in a Cerebral Infarction ...
Med Sci Monit In Press; DOI: 10.12659/MSM.933830
Most Viewed Current Articles
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700